Rebuttal from Ms Woodford and Dr Senthi

Katrina Woodford, Sashendra Senthi


Professor Nestle and Dr. Belderbos’ argument against the use of stereotactic body radiotherapy (SBRT) for central non-small cell lung cancer (NSCLC) centers on the fact there is little prospective high quality evidence to declare it safe. This is indeed true and highlights the importance of their multi-national phase II study (LungTech) and RTOG 0813 in guiding optimal patient care (1). However, there are aspects of their argument that should be discussed further, in particular data referenced from Cannon and Langendijk which may not be applicable to T2N0 central NSCLC.